Adding billions in value, Eli Lilly succeeds where Pfizer failed, halting breast cancer recurrence
For years, Eli Lilly played straggler behind Pfizer and Novartis on a new class of breast cancer drugs. Now they’ve succeeded in a key setting where Pfizer failed just 3 weeks ago.
In a nearly 6,000-person Phase III trial, patients with high risk hormone receptor/HER2 negative breast cancer who were given the Lilly drug Verzenio in combination with endocrine therapy were significantly less likely to have their cancer recur than patients who were given only endocrine therapy. Although Lilly did not release the specifics on the primary endpoint, called intensive disease free survival, these patients normally have a 30% chance of recurrence.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.